High density cultures led to a “gel-like” consistency post-harvest. Depth filtration failed prematurely (clogging at 30 L/m²). The high pI (8.2) of the mAb caused poor binding in standard Protein A columns when pH was adjusted to physiological range.
Led by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the N-mAb project brought together over 60 industry and government stakeholders to create a shared vocabulary and framework for a fully integrated continuous bioprocess for a hypothetical monoclonal antibody. This study explores crucial elements that are unique to continuous manufacturing, such as developing control strategies across an end-to-end process and managing deviations in real-time.
Defining the essential performance characteristics of the drug from a patient-centric perspective.
The harvest fluid contained significant cellular debris, host cell proteins, and DNA that required rigorous removal through a platform three-step purification process. Harvest and Clarification A Mab A Case Study In Bioprocess Development
Poros 50HS, pH 5.0, salt gradient.
Hydrophilic Interaction Liquid Chromatography (HILIC) confirmed that the low-fucosylation target was hit consistently across all development batches.
Upstream development focuses on maximizing volumetric productivity while ensuring the cell culture environment consistently yields the desired product quality. Cell Line Development (CLD) High density cultures led to a “gel-like” consistency
A Mab is a humanized monoclonal antibody targeting a specific antigen involved in the progression of a certain type of cancer. The antibody was developed to provide a more effective and targeted treatment option for patients with this disease. The development of A Mab involved a comprehensive bioprocess development program aimed at optimizing the production of high-quality material.
The polishing CEX step requires a 45 cm diameter column (Vantage VL). Packing at scale reveals a consistent "tilt" in the bed height. After four failed packs, the team switches to dynamic axial compression and reduces the slurry concentration from 50% to 35%, achieving a HETP (Height Equivalent to a Theoretical Plate) of <0.05.
To help refine this analysis or tailor it to your specific documentation needs, please let me know: g., ICH Q8/Q11 QbD principles)? Led by the National Institute for Innovation in
Final titer = 4.2 g/L, viability >75% at harvest. A 2.5-fold improvement over initial process.
The development team shifts from a traditional batch process to a fed-batch process with a chemically defined, animal-component-free medium. Using Design of Experiments (DoE), they optimize the feed strategy: